- Home
- XOMAP vs GBLI Comparison
XOMAP vs GBLI Comparison
Compare XOMAP & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- GBLI
- Stock Information
- Founded
- XOMAP N/A
- GBLI 2016
- Country
- XOMAP United States
- GBLI United States
- Employees
- XOMAP 13
- GBLI N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- GBLI Property-Casualty Insurers
- Sector
- XOMAP Health Care
- GBLI Finance
- Exchange
- XOMAP Nasdaq
- GBLI Nasdaq
- Market Cap
- XOMAP N/A
- GBLI N/A
- IPO Year
- XOMAP N/A
- GBLI 2003
- Fundamental
- Price
- XOMAP $26.08
- GBLI $34.98
- Analyst Decision
- XOMAP
- GBLI
- Analyst Count
- XOMAP 0
- GBLI 0
- Target Price
- XOMAP N/A
- GBLI N/A
- AVG Volume (30 Days)
- XOMAP N/A
- GBLI 2.5K
- Earning Date
- XOMAP N/A
- GBLI 11-07-2024
- Dividend Yield
- XOMAP N/A
- GBLI 4.00%
- EPS Growth
- XOMAP N/A
- GBLI 90.04
- EPS
- XOMAP N/A
- GBLI 2.92
- Revenue
- XOMAP N/A
- GBLI $442,500,000.00
- Revenue This Year
- XOMAP N/A
- GBLI N/A
- Revenue Next Year
- XOMAP N/A
- GBLI $8.41
- P/E Ratio
- XOMAP N/A
- GBLI $12.00
- Revenue Growth
- XOMAP N/A
- GBLI N/A
- 52 Week Low
- XOMAP N/A
- GBLI $26.50
- 52 Week High
- XOMAP N/A
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- XOMAP 52.06
- GBLI 66.82
- Support Level
- XOMAP $25.72
- GBLI $34.08
- Resistance Level
- XOMAP $26.00
- GBLI $36.38
- Average True Range (ATR)
- XOMAP 0.18
- GBLI 0.59
- MACD
- XOMAP -0.03
- GBLI 0.02
- Stochastic Oscillator
- XOMAP 49.64
- GBLI 40.06
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.